These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32272210)

  • 1. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
    Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
    Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
    Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
    Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.
    Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
    Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
    Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
    Int J Clin Oncol; 2023 Oct; 28(10):1237-1258. PubMed ID: 37599324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors.
    Mishima S; Naito Y; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E
    Int J Clin Oncol; 2023 Aug; 28(8):941-955. PubMed ID: 37300720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
    Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
    Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
    Yoshino T; Arnold D; Taniguchi H; Pentheroudakis G; Yamazaki K; Xu RH; Kim TW; Ismail F; Tan IB; Yeh KH; Grothey A; Zhang S; Ahn JB; Mastura MY; Chong D; Chen LT; Kopetz S; Eguchi-Nakajima T; Ebi H; Ohtsu A; Cervantes A; Muro K; Tabernero J; Minami H; Ciardiello F; Douillard JY
    Ann Oncol; 2018 Jan; 29(1):44-70. PubMed ID: 29155929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
    Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
    Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current Status and Challenges in Tumor Agnostic Treatment].
    Komine K
    Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.
    Mishima S; Taniguchi H; Akagi K; Baba E; Fujiwara Y; Hirasawa A; Ikeda M; Maeda O; Muro K; Nishihara H; Nishiyama H; Takano T; Tsuchihara K; Yatabe Y; Kodera Y; Yoshino T
    Int J Clin Oncol; 2020 Feb; 25(2):217-239. PubMed ID: 31286289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
    Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
    Thein KZ; Lemery SJ; Kummar S
    Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours].
    Rojo F; Colomer R; López-Ríos F; Bautista F; Álvarez R; de Álava E; Hladun R; Garrido P
    Rev Esp Patol; 2021; 54(4):250-262. PubMed ID: 34544555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.